Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mazin Yonan

Internal Medicine Troy, MI Medical Doctor

NPI 1801888904 CMS profile 217324

2221 Livernois Rd, 100, Troy, MI 48083

Open in the dashboard

General payments

$9,405

462 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mazin Yonan of Troy, MI is reported in the CMS Open Payments database as having received $9,405 across 462 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,403 56
2024 General $1,290 50
2023 General $1,348 65
2022 General $1,524 82
2021 General $1,617 88
2020 General $922 51
2019 General $1,300 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mazin Yonan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mazin Yonan were reported at $1,403. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mazin Yonan Internal Medicine median Middle half National median
2019 $1,300 $159 $48–$570 $163
2020 $922 $119 $33–$402 $114
2021 $1,617 $135 $37–$521 $132
2022 $1,524 $141 $42–$496 $149
2023 $1,348 $149 $45–$519 $160
2024 $1,290 $154 $47–$537 $164
2025 $1,403 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,497 69 payments
  2. Lilly USA, LLC $1,252 63 payments
  3. Amgen Inc. $1,057 59 payments
  4. AstraZeneca Pharmaceuticals LP $786 23 payments
  5. AbbVie, Inc. $758 32 payments
  6. Pfizer Inc. $576 34 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $325 18 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $248 14 payments
  9. Amarin Pharma Inc. $234 16 payments
  10. GlaxoSmithKline, LLC. $231 14 payments
  11. Other $2,439 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,293 460 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $111 1 payment
  3. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $943 51 payments
  2. RYBELSUS $835 39 payments
  3. TRULICITY $578 36 payments
  4. Repatha $541 28 payments
  5. JARDIANCE $529 35 payments
  6. AIRSUPRA $471 10 payments
  7. UBRELVY $459 20 payments
  8. MOUNJARO $444 16 payments
  9. Otezla $304 19 payments
  10. Prolia $280 17 payments
  11. Other $7,156 383 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 167 drugs

Part D claims

10,823

Median for Internal Medicine: 777

Drug cost

$1,285,275

Median for Internal Medicine: $73,373

Branded share of claims

25.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 215 $205,211
Jardiance Empagliflozin Brand 206 $188,304
Trulicity Dulaglutide Brand 105 $113,938
Mounjaro Tirzepatide Brand 56 $72,752
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 93 $69,494
Ozempic Semaglutide Brand 58 $58,895
Linzess Linaclotide Brand 73 $55,737
Rybelsus Semaglutide Brand 29 $43,135
Gemtesa Vibegron Brand 62 $40,513
Prolia Denosumab Brand 24 $40,417

The 10 drugs with the highest cost, of 167 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$158,329

Of which drugs: $91

Medicare patients

175

Average age 73

Services billed

2,613

105 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 59%
Ischemic heart disease 47%
Chronic kidney disease 38%
Osteoporosis 34%
Heart failure 30%
Atrial fibrillation 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 56 $53

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $180
$180 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $165
$165 62 —
UBRELVY
  • AbbVie, Inc. $142
$142 — —
RYBELSUS
  • Novo Nordisk Inc $55
$55 29 —
Ozempic
  • Novo Nordisk Inc $55
$55 58 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

462 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record